Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
for Major Depressive Disorder
Drug: NBI-1065845
40 locations incl. Huntsville
Sponsor: Neurocrine Biosciences
Sex: All·Age: 18+
Code: NCT06966401·Phase 3·Recruiting